Detection of a Novel Truncated WT1 Transcript in Human Neoplasia

Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ III: Transcriptional repressionmediated by the WT1 Wilms’ tumor gene product. Science 1991;253: 1550–1553 Madden SL, Cook DM, Rauscher FJ III: A structure-function analysis of transcriptional repression mediated by the WT1, Wilms’ tumor suppressor protein. Oncogene 1993;8: 1713–1720 Pritchard-Jones K, Fleming S, Davidson D, et al.: The candidate Wilms’ tumour gene is involved in genitourinary development. Nature 1990;346: 194–197 Schedl A, Hastie N: Multiple roles for the Wilms’ tumour suppressor gene, WT1 in genitourinary development. Mol Cell Endocrinol 1998;140: 65–69 Dong G, Rajah R, Vu T, et al.: Decreased expression of Wilms’ tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1997;82: 2198–2203 Englert C, Hou X, Maheswaran S, et al.: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14: 4662–4675 Wang ZY, Qiu QQ, Enger KT, Deuel TF: A second transcriptionally active DNA-binding site for the Wilms’ tumor gene product, WT1. Proc Natl Acad Sci U S A 1993;90: 8896–8900 Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ III: Repression of the insulin-like growth factor II gene by the Wilms’ tumor suppressor WT1. Science 1992;257: 674–678 Nichols KE, Re GG, Garvin AJ, Haber DA: WT1 induces expression of insulin-like growth factor 2 in Wilms’ tumor cells. Cancer Res 1995;4540-4543 Werner H, Roberts CT Jr, LeRoith D: The regulation of IGF-1 receptor gene expression by positive and negative zinc-finger transcription factors. Adv Exp Med Biol 1993;343: 91–103 Werner H, Rauscher FJ III, Sukhatme VP, Drummond IA, Roberts CT Jr, LeRoith D: Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 1994;269: 12577–12582 Shimamura R, Fraizer GC, Trapman J, Lau YFC, Saunders GF: The Wilms’ tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor. Clin Cancer Res 1997;3: 2571–2580 Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL: Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: Association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 1994;58: 721–729 Jackson-Cook CK: Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorigenic sublines M2182 and M15. Cancer Genet Cytogenet 1996;87: 14–23 Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL: Metastatic sublines of anSV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998;34: 275–282 Plymate SR, Tennant M, Birnbaum RS, Thrasher JB, Chatta G, Ware JL: The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab 1996;81: 3709–3716 Kaighn ME, Narayan KS, Ohnuki Y, Lechner JB, Jones LW: Establishment and characterization of a human prostate carcinoma cell line (PC-3). Invest Urol 1979;17: 16–23 Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 1987; 162: 156–159 Edmonds M, Vaughan MH Jr, Nakazato H: Polyadenylic acid sequences in the heterogeneous nuclear RNA and rapidly-labeled polyribosomal RNA of HeLa cells: Possible evidence for a precursor relationship. Proc Natl Acad Sci U S A 1971; 68: 1336–1340 Gessler M, Konig A, Bruns GA: The genomic organization and expression of the WT1 gene. Genomics 1992;12: 807–813 Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, New York, 1989 Bruening W, Pelletier J: A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem 1996;12: 8646–8654 Prats H, Kaghad M, Prats AC, et al.: High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons.Proc Natl Acad Sci U S A 1989;86: 1836–1840 Saris CJ, Domen J, Berns A: The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991;10: 655–664 Ohshima Y, Gotoh Y: Signal for the selection of splice site in pre-mRNA. Computer analysis of splice junction sequences and like sequences. J Mol Biol 1987;195: 247–259 Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D: Expression of the Wilms’ tumor gene WT1 in the murine urogenital system. Genes Dev 1991;5: 1345–1356 Walker C, Rutten R, Yuan X, Pass H, Mew DM, Everitt J: Wilms’ tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994; 54: 3101–3106 Coppes MJ, Campbell CE, Williams BR: The role of WT1 in Wilms tumorigenesis. FASEB J 1993;7: 886–895 Park S, Schalling M, Bernard A, et al.: The Wilms’ tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993;4: 415–420 King-Underwood L, Renshaw J, Pritchard-Jones K: Mutations in the Wilms’ tumor gene WT1 in leukemias. Blood 1996;87: 2171–2179 Pelletier J, Bruening W, Kashtan CE, et al.: Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991;67: 437–447 Barbaux S, Niaudet P, Gubler MC, et al.: Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997;17: 467–470